CPTx
CPTx is a preclinical-stage genetic medicines company developing in vivo CAR-T cell therapies via immune-silent single-stranded DNA vectors delivered with lipid nanoparticles, serving pharmaceutical and biotech partners through its gxstrands CDMO and platform licensing.
- Company typePrivate
- Founded2021
- HeadquartersPlanegg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CPTx does
CPTx is a preclinical-stage genetic medicines company developing in vivo CAR-T cell therapies using a proprietary immune-silent single-stranded DNA (ssDNA) vector platform delivered via non-viral targeted lipid nanoparticles (tLNPs). Founded in 2021 by Prof. Hendrik Dietz based on 15+ years of programmable DNA nanofabrication research at the Technical University of Munich, the company's core thesis is that immune-silent, episomal, redosable ssDNA vectors can deliver CAR-encoding genetic payloads directly to T cells in vivo — combining the durable expression of viral vectors with the safety and redosability of non-viral systems, and avoiding the transient kinetics of mRNA. Its lead proprietary program is an in vivo CD19/CD20 dual-targeting CAR T for relapsed/refractory B-cell non-Hodgkin lymphoma, with first-in-human clinical trials anticipated within 15-18 months from October 2025; the broader pipeline additionally includes a pan-influenza antiviral and at least two co-developed partnership assets.
CPTx operates a dual business model. On the therapeutic side, the company advances proprietary in vivo CAR-T and antiviral candidates toward commercialization through standard biopharma licensing and partnership structures. On the services side, its gxstrands wholly-owned subsidiary operates as a CDMO platform manufacturing custom, high-sequence-fidelity ssDNA constructs (up to 12kb and beyond, micrograms to grams) for external pharma and biotech customers engaged in gene editing, allogeneic CAR-T, and stem cell programs. The gxstrands unit both supports CPTx's own pipeline specifications and generates service-based revenue from external buyers. Strategic collaboration is exemplified by the EU Horizon Europe-funded QUIET-CAR project with NanoCell Therapeutics, which is developing tLNPs delivering CPTx's immune-silent ssDNA for in vivo CAR-T in cancer and autoimmune indications.
CPTx targets enterprise biopharma buyers through direct sales, co-development partnerships, and conference-led engagement (BIO, ESGCT, ASGCT, CAR-TCR Summit). The leadership team combines academic founders with senior pharma operators — Stefan Oschmann (Chairman, former CEO of Merck KGaA), Edward Rebar (CSO, former CTO of Sangamo and Sana Biotechnology), Grant Boldt (COO, ex-Lonza and Sigma-Aldrich), David Maier (CBO, ex-Novartis, West, Lonza, L.E.K.), and CFO McDavid Stilwell — supported by an 11-50 employee organization across Munich/Planegg, Germany and South San Francisco, California. The company closed a $29M seed round in September 2024 led by Blueyard Capital and SPRIND.
CPTx firmographics
Firmographics- Name
- CPTx
- Legal name
- CPTx GmbH
- Website
- https://cptx.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CPTx is a preclinical-stage genetic medicines company developing in vivo CAR-T cell therapies via immune-silent single-stranded DNA vectors delivered with lipid nanoparticles, serving pharmaceutical and biotech partners through its gxstrands CDMO and platform licensing.
- Ownership category
- akta.pro rank
CPTx industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)
- akta.pro secondary industries
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where CPTx is headquartered
LocationHeadquarters
- HQ city
- Planegg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
CPTx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Therapeutic Pipeline Development and Commercialization: CPTx develops proprietary in vivo CAR-T therapeutic candidates from its ssDNA platform, advancing programs such as a CD19/CD20 dual-targeting CAR T for relapsed/refractory B-NHL toward clinical trials. The company plans to commercialize its lead programs once clinical development is completed, targeting oncology and autoimmune disease markets.
- CDMO Services (gxstrands): CPTx operates its ssDNA manufacturing unit, gxstrands, as a CDMO platform providing high-quality knock-in templates for gene editing applications to pharmaceutical and biotech companies. This includes allogeneic CAR-T and stem cell editing services. Revenue is generated through service contracts and manufacturing agreements with external pharma partners.
- Platform Licensing and Partnership Deals: CPTx generates revenue through strategic partnerships and licensing arrangements with biopharma companies seeking access to its ssDNA platform technology, DNA nanofabrication capabilities, and proprietary delivery systems. The company has multiple partnership assets and collaborates on co-development programs.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
CPTx product offering
Product offeringCore offering
CPTx develops immune-silent single-stranded DNA (ssDNA) vectors delivered with targeted lipid nanoparticles (LNPs) to enable in vivo CAR-T cell therapies that are durable, redosable, and tunable, avoiding the integration risks of viral vectors and the transient expression of mRNA. The company's lead proprietary program is an in vivo CD19/CD20 dual-targeting CAR T for relapsed/refractory B-cell non-Hodgkin lymphoma. CPTx also operates gxstrands, an in-house CDMO platform that manufactures custom high-sequence-fidelity ssDNA constructs up to 12kb at microgram to gram scales for gene editing and cell therapy programs of external pharma and biotech partners.
Product overview
CPTx is a genetic medicines company offering a proprietary immune-silent ssDNA + LNP platform as its core technology for developing in vivo CAR-T cell therapies. The company's primary therapeutic product is an in vivo CD19/CD20 dual-targeting CAR T for relapsed/refractory B-NHL. The platform enables durable expression, repeat dosing, and immune silence without the complexity or toxicity of viral vectors or mRNA. Additionally, CPTx offers gxstrands, an internal CDMO platform providing high-quality ssDNA manufacturing services for gene editing applications.
Differentiator
Problem solved
Functional benefit
Products and services
- ssDNA + LNP Platform CPTx's proprietary immune-silent single-stranded DNA (ssDNA) vector platform delivered via targeted lipid nanoparticles (tLNPs), enabling durable, redosable, and tunable in vivo CAR-T therapies without viral integration or mRNA limitations. Licensed and partnered with biopharma for cell and gene therapy programs.
- In Vivo CD19/CD20 Dual-Targeting CAR T Program Lead proprietary development program targeting relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) using CPTx's immune-silent ssDNA delivered with LNPs to enable repeat dosing and controllable long-lasting effects in patients.
- gxstrands CDMO Services Contract development and manufacturing organization providing custom, high-sequence-fidelity single-stranded DNA constructs up to 12kb and beyond at microgram to gram scales, including knock-in templates for allogeneic CAR-T and stem cell editing applications.
Quantifiable outcome
- Preclinical data demonstrates more durable tumor control with ssDNA-based CAR-T relative to mRNA-based particles in mouse models, consistent with more sustained and controllable expression profiles
Companies that use CPTx
Customer profileSegments3 records
Ideal customer profiles2 records
CPTx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
CPTx partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and foundational.
- NanoCell TherapeuticscoreCollaborative QUIET-CAR project awarded a Eurostars Grant from the EU Horizon Europe program and Eureka Network. The project focuses on developing targeted lipid nanoparticles carrying novel immune-silent ssDNA for in vivo CAR T therapy targeting cancer and autoimmune diseases. Top-ranked among 120+ Eurostars Grant submissions. NanoCell Therapeutics is a privately held biotech company pioneering in vivo cell engineering through non-viral, DNA-based gene therapy.
- Technical University of Munich (TUM)foundationalCPTx was founded to translate 15+ years of foundational research in ssDNA engineering, programming, and manufacturing conducted at TUM by Prof. Hendrik Dietz. The company maintains academic and research ties to TUM and has peer-reviewed publications co-authored with TUM researchers.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
CPTx competitors and assessment
Company assessmentEmerging players
- Kelonia Therapeutics: Kelonia is an early-stage biotech developing in vivo CAR-T using LNP delivery of genetic cargo, with a comparable preclinical platform narrative and similar target indications in oncology.
- Orna Therapeutics: Orna is developing in vivo cell therapies using circular RNA delivered via LNP, an adjacent non-viral approach competing for the same redosable, durable gene expression niche as CPTx's ssDNA.
Direct peers
- Umoja Biopharma: Umoja is developing in vivo CAR-T therapies using its RACR platform (lentiviral delivery to immune cells), competing directly with CPTx in the in vivo CAR-T space with overlapping B-cell malignancy and broader oncology targets.
- Interius BioTherapeutics: Interius is a direct in vivo CAR-T competitor using viral vectors to generate CAR-T cells inside the body, targeting B-cell malignancies with a similar preclinical-to-clinical trajectory and competing for the same biopharma partnership interest.
- Capstan Therapeutics: Capstan developed in vivo cell therapy using LNP-mRNA delivery to reprogram immune cells, the most direct non-viral peer to CPTx's LNP-ssDNA approach; acquired by AbbVie in 2025, validating strategic interest in the in vivo CAR-T category.
Broad incumbents
- Sana Biotechnology: Sana is a clinical-stage cell engineering company developing in vivo and ex vivo cell therapies across oncology and genetic diseases; comparable in therapeutic ambition, and CPTx's new CSO Edward Rebar previously served as Sana's CTO, creating direct talent and technology overlap.
- Cellectis: Cellectis is a clinical-stage gene editing company pioneering allogeneic CAR-T, broadly comparable in therapeutic category (engineered cell therapies for oncology) and a long-standing reference point for cell therapy platform economics.
- Beam Therapeutics: Beam is a clinical-stage gene editing company using LNP delivery of base editing cargo in vivo, comparable to CPTx in combining non-viral delivery with precision genetic medicines for both rare diseases and oncology.
Others
- Aldevron: Aldevron is a leading nucleic acid CDMO providing plasmid, mRNA, and protein manufacturing services to gene and cell therapy developers; directly comparable to CPTx's gxstrands CDMO business and a benchmark for CDMO unit economics and scale.
- Acuitas Pharmaceuticals: Acuitas develops lipid nanoparticle delivery technology used in mRNA vaccines and therapeutics, including supplying LNPs to multiple in vivo cell therapy developers; a critical enabling technology provider and ecosystem comparable to CPTx's LNP delivery approach.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
CPTx social profiles
Digital presenceCPTx financial estimates
Financial estimateRevenue estimate
Valuation estimate
CPTx leadership team
Management profileNumber of profiles
Profiles7 records
CPTx subsidiaries and ownership
Company hierarchySubsidiaries1 record
CPTx funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CPTx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CPTx
What does CPTx do?
CPTx develops immune-silent single-stranded DNA (ssDNA) vectors delivered with targeted lipid nanoparticles (LNPs) to enable in vivo CAR-T cell therapies that are durable, redosable, and tunable, avoiding the integration risks of viral vectors and the transient expression of mRNA. The company's lead proprietary program is an in vivo CD19/CD20 dual-targeting CAR T for relapsed/refractory B-cell non-Hodgkin lymphoma. CPTx also operates gxstrands, an in-house CDMO platform that manufactures custom high-sequence-fidelity ssDNA constructs up to 12kb at microgram to gram scales for gene editing and cell therapy programs of external pharma and biotech partners.
Is CPTx a public or private company?
CPTx is a private company. It is classified as venture growth investor backed and is currently operating.
When was CPTx founded?
CPTx was founded in 2021. It employs 11 to 50 people.
Where is CPTx based?
CPTx is headquartered in Planegg, Germany, in the Europe region.
How does CPTx make money?
Three revenue lines are on record. Therapeutic Pipeline Development and Commercialization is the primary driver. The others are CDMO Services (gxstrands) and platform Licensing and Partnership Deals.
Who are CPTx's main competitors?
Emerging players on record are Kelonia Therapeutics and Orna Therapeutics. Direct peers are Umoja Biopharma, Interius BioTherapeutics and Capstan Therapeutics. Broad incumbents are Sana Biotechnology, Cellectis and Beam Therapeutics. Others are Aldevron and Acuitas Pharmaceuticals.
Does CPTx have an API?
No public API is recorded for CPTx.
What industry is CPTx in?
CPTx's product category is Cell Therapy. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 541714 and its SIC code is 2836.